Candesartan vs Durvalumab

Candesartan vs Durvalumab: Overview

This comparison examines the pharmacological differences between Candesartan and Durvalumab.

Mechanism of Action

Candesartan: Prodrug hydrolyzed to active form; selective angiotensin II type 1 receptor blocker.

Durvalumab: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

Pharmacokinetics

Half-life: Candesartan — 9 hours; Durvalumab — 17 days.

Chemical Properties

Molecular Formula: Candesartan — C33H34N6O6.

Molecular Weight: Candesartan — 610.6640 g/mol.

Type: Candesartan — Small molecule; Durvalumab — Antibody.